<i>HER-2</i> Expression and Cell Proliferation: Prognostic Markers in Patients With Node-Negative Breast Cancer

Abstract

HER-2 expression in association with proliferative activity identifies a subgroup of node-negative breast cancer patients with the worst prognosis, who are candidates for specific intensive adjuvant therapy.